BLC
SPRY icon

Brown, Lisle/Cummings’s ARS Pharmaceuticals SPRY Stock Holding History

Brown, Lisle/Cummings’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.2K Hold
400
– – ﹤0.01% 770
2026
Q1 		$3.21K Hold
400
– – ﹤0.01% 738
2025
Q4 		$4.66K Hold
400
– – ﹤0.01% 562
2025
Q3 		$4.02K Hold
400
– – ﹤0.01% 589
2025
Q2 		$6.98K Hold
400
– – ﹤0.01% 539
2025
Q1 		$5.03K Hold
400
– – ﹤0.01% 555
2024
Q4 		$4.22K Hold
400
– – ﹤0.01% 548
2024
Q3 		$5.8K Buy
+400
New +$4.76K ﹤0.01% 504

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Brown, Lisle/Cummings's SPRY Position: Q2 2026 in Review

Brown, Lisle/Cummings held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 400 shares worth $3.2K. The position accounts for ﹤0.01% of the portfolio, ranked #770.

Brown, Lisle/Cummings first reported a position in SPRY in Q3 2024 and has held it in 8 quarters since. The position peaked at $6.98K in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Brown, Lisle/Cummings held 400 shares of ARS Pharmaceuticals worth $3.2K as of Q2 2026.
  • Brown, Lisle/Cummings left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #770 holding.
  • Brown, Lisle/Cummings first reported a position in ARS Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Brown, Lisle/Cummings's ARS Pharmaceuticals position peaked at $6.98K in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.